Law360, New York (July 12, 2010, 4:30 PM ET) -- Promote Innovation LLC has accused Medtronic Inc. of falsely marking its stents with patents found unenforceable due to inequitable conduct.
Medtronic had no right to mark its Endeavor stent system and other products with two patents declared unenforceable in court, according to a qui tam suit Promote Innovation filed Friday in the U.S. District Court for the Eastern District of Texas.
Zachariah Harrington, an attorney at Antonelli Harrington & Thompson LLP who represents the plaintiff, said the patents were found to be unenforceable in 2008, and...
Medtronic Faces False Marking Suit Over Stents
To view the full article, take a free trial now.
